NLRP3 and atherosclerosis: For instance, selective NLRP3 inhibitor MCC950 can hinder atherosclerosis development by attenuating inflammatory responses and macrophage activation in ApoE−/− mice and ox-LDL-induced THP-1-derived macrophages [13].